Chemistry:Adhansia XR
 | |
| Clinical data | |
|---|---|
| Pronunciation | Methylphenidate hydrochloride |
| Trade names | Foquest, Adhansia XR |
| Pregnancy category |
|
| Routes of administration | By mouth (capsules or powder) |
| Drug class | CNS stimulant |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Duration of action | 16 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C14H19NO2 |
| Molar mass | 233.311 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Adhansia XR is a pharmaceutical medication used to treat attention deficit hyperactivity disorder (ADHD) in patients six years and older.[1][2][3] Also known by the trade name Foquest,[4] the extended-release capsules are taken once daily[1] and last up to 16 hours. The active ingredient is methylphenidate hydrochloride,[5] which stimulates the central nervous system to increase focus and lessen the symptoms of ADHD.[1]
The most common side effects of Adhansia XR include insomnia, dry mouth, and decreased appetite. Other adverse reactions to methylphenidate have included dependence, cardiovascular issues, psychiatric issues, vascular disease, growth suppression, and allergic reactions.[6] The recommended starting dose for Adhansia XR is 25 milligrams, with medication available in six capsule strengths.[1]
Patented and manufactured by Purdue Pharma Canada[4] and Adlon Therapeutics,[1] Adhansia XR has been commercially available in Canada as Foquest since 2018. It was the first methylphenidate product in Canada to have a 16-hour duration.[4] The medication was approved in the United States by the Food and Drug Administration on March 1, 2019.[1][7][3] Adlon announced they planned to release the drug later in 2019.[6]
On April 2, 2019, it was reported that Purdue Pharma was seeking a new ad agency for an undisclosed "new product," leading to speculation that the contract was to market Adhansia XR in the United States.[8] Purdue clarified that it did not intend to use direct-to-consumer advertising for Adhansia XR, and would instead focus on "ensuring the responsible prescribing and use" of the drug.[9]
Medical uses
ADHD treatment
- For more detail, see: Methylphenidate and ADHD
Adverse effects
- For more detail, see: Adverse effects of methylphenidate
Pharmacology
- Main article: Methylphenidate pharmacodynamics
Studies
The FDA approved Adhansia XR using the results of four clinical studies, which included involving 883 patients in controlled studies.[1]
See also
- Attention deficit hyperactivity disorder management
- List of methylphenidate analogues
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "FDA approves Purdue Pharma subsidiary’s ADHD drug". Houston Chronicle. March 1, 2019. https://www.chron.com/business/article/FDA-approves-Purdue-Pharma-subsidiary-s-ADHD-13655418.php.
"FDA approves Purdue Pharma subsidiary’s ADHD drug". San Antonio Express-News. March 1, 2019. https://www.mysanantonio.com/business/article/FDA-approves-Purdue-Pharma-subsidiary-s-ADHD-13655418.php.
"FDA approves Purdue Pharma subsidiary’s ADHD drug". Stamford Advocate. March 1, 2019. https://www.stamfordadvocate.com/business/article/FDA-approves-Purdue-Pharma-subsidiary-s-ADHD-13655418.php. - ↑ "FDA approves Adhansia XR for ADHD". Psychiatric Annals. March 1, 2019. https://www.healio.com/psychiatry/add-adhd/news/online/%7B8a67c4be-4ddd-40af-a908-91ba52c3f754%7D/fda-approves-adhansia-xr-for-adhd. Retrieved August 28, 2019.
- ↑ 3.0 3.1 "Sacklers quit Purdue Pharma board amid shifts for OxyContin maker". Stamford Advocate. April 7, 2019. https://www.stamfordadvocate.com/business/article/Sacklers-quit-Purdue-Pharma-board-signaling-13742946.php. Retrieved May 22, 2019.
- ↑ 4.0 4.1 4.2 "New Treatment Option for Adults with ADHD: Foquest Now Available in Canada". Purdue Pharma. February 1, 2018. https://purdue.ca/en/2018/02/01/new-treament-option-for-adults-with-adhd-foquest-methylphenidate-controlled-release-capsules-now-available-in-canada/. Retrieved August 28, 2019.
- ↑ "Medication Options for Treating ADHD". US News. May 31, 2019. https://health.usnews.com/conditions/adhd/articles/adhd-medications. Retrieved August 28, 2019.
- ↑ 6.0 6.1 "XR (methylphenidate HCl) Extended-Release Capsules CII for the Treatment of ADHD". Adlon Therapeutics. March 1, 2019. https://www.businesswire.com/news/home/20190301005270/en/Adlon-Therapeutics-L.P.-Announces-FDA-Approval-Adhansia. Retrieved August 28, 2019.
- ↑ "OxyContin maker Purdue Pharma exits sleep-drug partnership". San Francisco Chronicle. May 1, 2019. https://www.sfchronicle.com/business/article/OxyContin-maker-Purdue-Pharma-exits-sleep-drug-13810353.php?psid=5Ss7e. Retrieved August 28, 2019.
- ↑ "OxyContin Maker Purdue Pharma Seeks New Ad Agency Partner". Adweek. April 2, 2019. https://www.adweek.com/agencies/oxycontin-maker-purdue-pharma-seeks-new-ad-agency-partner/. Retrieved August 28, 2019.
- ↑ "Under-fire Purdue hunts for ad agency to promote upcoming product: report". FiercePharma. April 2, 2019. https://www.fiercepharma.com/marketing/purdue-hunt-for-ad-agency-to-promote-upcoming-product-adweek. Retrieved August 28, 2019.
 |
